Target
ICP34.5
2 abstracts
Abstract
The initial report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors.Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, Banner MD Anderson Cancer Center, Gilbert, AZ, Virogin Biotech, Jonesville, FL, Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Virogin Biotech (Shanghai) Ltd, Shanghai, China,
Abstract
A phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors.Org: Fudan University Shanghai Cancer Center, Department of Orthopedics, the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Department of Hematology ,ZheJiang provincial people’s hospital, Department of Oral and Maxillofacial Head & Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China,